Sugi Predict

Sugi Predict / Compounds / SCHEMBL3518477

SCHEMBL3518477

SCHEMBL3518477

COC(=O)c1c(OC)c(F)cc2nccnc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 1/20 0.37
▸ MAPK9 P45984 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ HTT P42858 4/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ TUBB1 Q9H4B7 1/20 0.35
▸ PDE4A P27815 1/20 0.34
▸ SMN1; SMN2 Q16637 4/20 0.33
▸ MAPT P10636 4/20 0.33
▸ POLB P06746 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.33
▸ CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521595 0.82 MAPT (0.37) MAPK8MAPK9MAPK10HTTALOX15
SCHEMBL3521880 0.82 ALDH1A1 (0.39) MAPK8MAPK9MAPK10HTTALOX15
SCHEMBL3520012 0.80 MAPK8 (0.35) MAPK8MAPK9MAPK10HTTALOX15
SCHEMBL3520015 0.78 MAPK8 (0.39) MAPK8MAPK9MAPK10HTTALOX15
SCHEMBL3530106 0.75 CFTR (0.43) MAPK8MAPK9MAPK10HTTALOX15
SCHEMBL9766054 0.73 CA1 (0.44) TUBB1SMN1; SMN2MAPTPOLBMEN1
SCHEMBL24338023 0.71 MAPT (0.46) HTTALOX15SMN1; SMN2MAPTPOLB
SCHEMBL30805790 0.71 CYP3A4 (0.45) HTTTUBB1SMN1; SMN2MAPTPOLB
SCHEMBL27302834 0.71 CYP3A4 (0.45) HTTTUBB1SMN1; SMN2MAPTPOLB
SCHEMBL3758964 0.71 MEN1 (0.54) MAPK8MAPK9MAPK10HTTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 — — CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 — — US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 — — US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 — — US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 — — EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 — — WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 MAPK8 3644/4885MAPK9 3627/4885MAPK10 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.